Cardioprotection: Emerging pharmacotherapy

R. J. Gumina, A. Jahangir, G. J. Gross, A. Terzic

Research output: Contribution to journalReview article

8 Scopus citations

Abstract

By the year 2020, it is predicted that acute coronary occlusion will be the major cause of death in the world. Recent advances in reperfusion therapy have substantially improved survival of patients with acute coronary syndromes. While early reperfusion reduces mortality, a time limitation exists with regard to myocardial salvage. In fact, the major limiting factor in further improving survival of patients with myocardial ischaemia is the susceptibility of the cardiomyocyte to ischaemic insult and lethal cell injury. Over the last decade substantial progress has been made in our understanding of the fundamental mechanisms of ischaemia/reperfusion injury. From this work novel means which limit or delay myocyte death have emerged and are currently under development as therapeutic candidates for the management of acute coronary syndromes. This report examines cardioprotective mechanisms and reviews clinical evidence for myocardial protective therapies.

Original languageEnglish (US)
Pages (from-to)739-752
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume2
Issue number5
DOIs
Publication statusPublished - Aug 27 2001

    Fingerprint

Keywords

  • Adenosine
  • Antineutrophils
  • Cardioprotection
  • Clinical trials
  • Magnesium
  • Myocardial infarction
  • Opioids
  • Potassium channel openers
  • Sodium-hydrogen exchanger inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Gumina, R. J., Jahangir, A., Gross, G. J., & Terzic, A. (2001). Cardioprotection: Emerging pharmacotherapy. Expert Opinion on Pharmacotherapy, 2(5), 739-752. https://doi.org/10.1517/14656566.2.5.739